Armata Price Earnings To Growth Ratio from 2010 to 2025

ARMP Stock  USD 1.58  0.07  4.24%   
Armata Pharmaceuticals Price Earnings To Growth Ratio yearly trend continues to be relatively stable with very little volatility. Price Earnings To Growth Ratio is likely to drop to 0.05. During the period from 2010 to 2025, Armata Pharmaceuticals Price Earnings To Growth Ratio destribution of quarterly values had range of 0.5004 from its regression line and mean deviation of  0.07. View All Fundamentals
 
Price Earnings To Growth Ratio  
First Reported
2010-12-31
Previous Quarter
0.04862576
Current Value
0.0462
Quarterly Volatility
0.11347298
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Armata Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Armata Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Selling General Administrative of 12.5 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 28.2, Dividend Yield of 0.0175 or Days Sales Outstanding of 256. Armata financial statements analysis is a perfect complement when working with Armata Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Armata Pharmaceuticals Correlation against competitors.
To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.

Latest Armata Pharmaceuticals' Price Earnings To Growth Ratio Growth Pattern

Below is the plot of the Price Earnings To Growth Ratio of Armata Pharmaceuticals over the last few years. It is Armata Pharmaceuticals' Price Earnings To Growth Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Armata Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Price Earnings To Growth Ratio10 Years Trend
Very volatile
   Price Earnings To Growth Ratio   
       Timeline  

Armata Price Earnings To Growth Ratio Regression Statistics

Arithmetic Mean0.04
Geometric Mean0.01
Coefficient Of Variation292.49
Mean Deviation0.07
Median0
Standard Deviation0.11
Sample Variance0.01
Range0.5004
R-Value0.01
Mean Square Error0.01
R-Squared0.00008
Significance0.97
Slope0.0002
Total Sum of Squares0.19

Armata Price Earnings To Growth Ratio History

2025 0.0462
2024 0.0486
2023 -0.022
2022 -0.0922
2021 0.18
2020 0.0502
2019 0.0184

About Armata Pharmaceuticals Financial Statements

Armata Pharmaceuticals shareholders use historical fundamental indicators, such as Price Earnings To Growth Ratio, to determine how well the company is positioned to perform in the future. Although Armata Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Armata Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Armata Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Price Earnings To Growth Ratio 0.05  0.05 

Additional Tools for Armata Stock Analysis

When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.